BCG Sii

BIOLOGICAL4 trials

Sponsors

University of Oxford, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Serum Institute of India Private Limited

Conditions

Mycobacterium Tuberculosis InfectionTuberculosisTuberculosis (TB)

Phase 2

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)

RecruitingNCT06997367

Bharat Biotech International LimitedTuberculosis (TB)

Start: 2025-03-01End: 2026-06-30Target: 164Updated: 2025-05-30

Phase 3

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

CompletedNCT04351685

Serum Institute of India Pvt. Ltd.Mycobacterium Tuberculosis Infection

Start: 2020-11-09End: 2024-10-30Updated: 2025-02-10

Study to Evaluate the Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Mycobacterium Tuberculosis Infection in Newborn Infants at multiple sites

Active, not recruitingPACTR202007868402718

Serum Institute of India Private LimitedTuberculosis

Start: 2020-10-31Target: 6940Updated: 2026-01-27

Unknown Phase

Heterologous Effects of BCG in Healthy UK Adults

CompletedNCT02380508

University of OxfordTuberculosis

Start: 2015-02-28End: 2016-11-30Updated: 2016-11-30

Related Papers

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study

Scientific Reports2022-05-126 citations